CEO, William Resides announces that as of July 1st, 2022, BioRegenx has moved from due diligence to a binding letter of intent to merge with a public company. These steps also include drafting of the definitive agreement for final merger. As part of the merger activity, BioRegenx has hired Dan Cortes, CPA as its CFO. This decision was made in part to Dan’s track record as an experienced corporate financial CFO with more than 20 years of progressive experience in financial operations and taxation with both private and public organizations ranging from startups to those with hundreds of millions in revenue. Microvascular Health Solutions Developments After 18-months of research and development, followed by rigorous testing, Microvascular Health Solutions has approved final production of a new camera capable of taking six times more video images gathered from under the tongue. The new patent-pending camera is called CapiVision™. The components for 1,000 CapiVision cameras have been ordered and production has begun with delivery expected late Q3, early Q4. Along with development of the new CapiVision camera, the MVHS team has completed development of the 5.2.7 version of the GlycoCheck software and new video acquisition software that quality-check videos recorded by the CapiVision camera.   Read more…